LONDON, June 9, 2021 /PRNewswire/ -- Hikma
Pharmaceuticals PLC (Hikma), the multinational
pharmaceutical company, announces that Patrick Genestin has been appointed Vice
President, Business Development, Generics. Mr. Genestin brings to
Hikma more than 25 years of experience in the pharmaceutical
industry as a results-driven executive with strong financial,
business development and M&A experience. He will be based at
the company's US headquarters in Berkeley
Heights, NJ.
In this role, Mr. Genestin is responsible for driving pipeline
strategy and identifying new growth opportunities for Hikma's
Generics business, including leading the execution of licensing and
M&A deals, proactively identifying business development
opportunities and maintaining and growing Hikma's contract
manufacturing (CMO) business.
"Patrick is an established business development leader whose
extensive industry experience will be critical to Hikma as we build
on our successful track record," said Brian
Hoffmann, President, Hikma Generics. "His expertise will be
instrumental in helping us to develop new partnerships and acquire
new products that will bolster our differentiated pipeline. He will
also work to leverage our state-of-the-art Columbus, Ohio manufacturing facility by
identifying new contract manufacturing opportunities, and will
explore new growth areas including commercializing our portfolio
outside of the US."
"I am excited to be joining Hikma at an important time for the
company and the Generics business," said Mr. Genestin. "With its
strong manufacturing capabilities and outstanding facilities,
excellent quality record, and proven ability to commercialize,
Hikma's Generics business has long been seen as a partner of choice
in the industry. I look forward to working together with Hikma's
excellent team to build on this position of strength, lead our
pipeline strategy, help deliver continued growth and ensure that
important generic medicines continue to be made available to the
patients who rely on them."
Prior to joining Hikma, Mr. Genestin served as Vice President,
Business Development & Licensing and Mergers & Acquisitions
for the US entity of Sandoz, Inc. A native of France, Mr. Genestin received his bachelor's
degree from L'Ecole Superieure de
Commerce de Nantes and holds an M.B.A. in Finance from Penn
State University.
Enquiries
Hikma Pharmaceuticals PLC
Susan
Ringdal
EVP, Strategic
Planning and Global Affairs
|
+44 (0)20 7399 2760/
+44 7776 477050
uk-investors@hikma.uk.com
|
Steve
Weiss
David
Belian
US Communications and
Public Affairs
|
+1 732 720 2830/ +1
732 788 8279
+1 732 720 2814/+1
848 254 4875
uscommunications@hikma.com
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the
United States (US), the Middle
East and North Africa
(MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,600 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hikma-appoints-patrick-genestin-to-lead-generics-business-development-301308368.html
SOURCE Hikma Pharmaceuticals USA Inc.